◆ AI Clinical Summary
Plain-language summary for patients
| NCT ID | NCT03280394 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oncology Institute of Southern Switzerland |
| Condition | Mature B-Cell Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 444 participants |
| Start Date | 2017-09-01 |
| Primary Completion | 2027-12-31 |
Trial Parameters
Condition Mature B-Cell Neoplasm
Sponsor Oncology Institute of Southern Switzerland
Study Type OBSERVATIONAL
Phase N/A
Enrollment 444
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2017-09-01
Completion 2027-12-31
Interventions
Liquid Biopsy
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The study aims at assessing whether cell free DNA genotyping can improve the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that refine the diagnostic workup, stratify prognosis and identify the emergence of drug-resistance mutations during treatment.
Eligibility Criteria
Inclusion Criteria: * Male or female adults 18 years or older * Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria * Willing and able to comply with scheduled study procedures * Evidence of a signed informed consent
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology